Treatment of B cell cancers using a combination comprising Btk inhibitors

US11701357B2 · kind B2 · utility

Assignee

• Beigene Switzerland GMBH · CH

Inventors

• Nan-Xing Hu · Oakville, CA
• Lai-Xi Wang · Dallas, US
• Jing Song · Sha Tin, CN
• Tong Zhang · Beijing, CN
• Kang Li · Sammamish, US
• Lusong Luo · Beijing, CN
• Min Wei · Beijing, CN
• Zhiwei Wang · Beijing, CN
• Yunhang Guo · Beijing, CN

Key dates

• Filing date: Aug 18, 2017
• Grant date: Jul 18, 2023
• Expiry date: Jun 6, 2038

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K2039/505
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed herein is a method for the prevention, delay of progression or treatment of cancer in a subject, comprising administering to the subject in need thereof a Btk inhibitor, particularly, (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide or a pharmaceutically acceptable salt thereof, in combination with an immune checkpoint inhibitor or a targeted therapy agent. Also, disclosed a pharmaceutical combination comprising a Btk inhibitor, particularly, (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide or a pharmaceutically acceptable salt thereof, in combination with an immune checkpoint inhibitor, or a targeted therapy agent and the use thereof.